Brainy efforts underway, but still some way to go for neuro drug developers
Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3%
Cons Disc leads S&P sector gainers; Utilities sole loser
Euro STOXX 600 index up 1.3%
Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4%
U.S. 10-Year Treasury yield edges up to ~4.33%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com
BRAINY EFFORTS UNDERWAY, BUT STILL SOME WAY TO GO FOR NEURO DRUG DEVELOPERS
An unmet need in neurological conditions has stirred up anticipation for trial data for drugs being developed for neurological conditions like depression, Alzheimer's disease, and dementia that affect millions of patients worldwide, Canaccord Genuity analysts said on Friday.
The brokerage said some recent wins with Eisai 4523.T and Biogen's BIIB.O Leqembi and Eli Lilly's LLY.N Kisunla for Alzheimer's, along with Bristol Myers Squibb's BMY.N Cobenfy for schizophrenia, represent significant advances in their fields.
It estimates that about 57 products are in development for major depressive disorder, including 14 for treatment-resistant depression, 11 for bipolar depression, and 5 for postpartum depression that affects new mothers.
Canaccord said it is looking forward to late-stage trial data from Johnson & Johnson's JNJ.N aticaprant and Neumora Therapeutics' NMRA.O navacaprant, both in development for major depressive disorder.
"Overall, we believe biopharma's depression-focused pipeline remains healthy" said Canaccord, but added that there was still a long way to go due to some diseases being poorly understood.
Canaccord added that successes in Alzheimer's with Leqembi and Kisunla have come despite the challenges in understanding such neurodegenerative conditions.
Among newer drugs in development, the brokerage highlighted Roche's ROG.S trontinemab, designed to ferry the drug across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of getting more of the treatment into the brain.
Canaccord said Cervomed's CRVO.O neflamapimod could be a "major advance for patients."
Cervomed is developing the drug to treat dementia with Lewy bodies, the second most common type of dementia after Alzheimer's and an indication that sees fewer investments, said Canaccord.
(Christy Santhosh)
*****
FOR FRIDAY'S EARLIER LIVE MARKETS POSTS:
JOBS REPORT DRILL-DOWN: IS DIRE DATA A BLIP OR TREND? - CLICK HERE
U.S. STOCKS RISE AFTER PAYROLLS AS AMAZON LEADS - CLICK HERE
U.S. STOCK FUTURES ADD SLIGHTLY TO GAINS, YIELDS FALL, AFTER JOBS DISAPPOINT - CLICK HERE
COULD OCTOBER PAYROLLS BE NEGATIVE? - CLICK HERE
EUROPEAN EARNINGS: BETTER BUT STILL MIXED - MORGAN STANLEY - CLICK HERE
UK GILTS: TRUSSED UP? - CLICK HERE
EUROPEAN SHARES BOUNCE, STILL SET FOR WEEKLY FALL - CLICK HERE
EUROPE BEFORE THE BELL: FUTURES STEADY BEFORE JOBS DATA - CLICK HERE
A NOVEMBER TO REMEMBER... -CLICK HERE
Early trade Nov 1 https://tmsnrt.rs/4f6WHRV
Nonfarm payrolls https://reut.rs/3AaNOYA
Inflation gauges https://reut.rs/40sVSP5
Labor market participation https://reut.rs/4easqAj
Unemployment by duration https://reut.rs/3YKrmPl
Unemployment by race and ethnicity https://reut.rs/48u6jDK
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
